Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N... see more

Bullboard (CSE:AGN)

View:
Prev 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ... Next
Post by SkywalkerofLukeon Apr 27, 2023 3:36pm

CEO Interview

More than 1 in 7, that is 15% of US adults or 37 million people, are estimated to have chronic kidney disease and as many as 9 in 10 adults do not know they have it. AGN.c AGNPF is looking to ...more  
101
Post by nodaytraderon Apr 27, 2023 12:51pm

Here we go again

Price down again, from 27 to 26 on one measly trade $130 from guess who? Integral
75
Post by SkywalkerofLukeon Apr 26, 2023 4:37pm

Recent News

AGN.c AGNPF is continuing to be a leader in the discovery of new therapeutic uses for drugs that are off patent and have a well-known safety history, but have never been marketed in the U.S. or Europe ...more  
108
Post by nodaytraderon Apr 26, 2023 12:00pm

Trading Down

Price down again in early trading from 29 cents to 27.5. and who is trading? Integral and National Bank and PI Financial. And no big trades.
99
Post by nodaytraderon Apr 25, 2023 5:23pm

That’s Odd -Continued

At the end of the day just before close. Two trades thar drop the price from 30 cents to 29 cents, from the same two players - Intergral and National Bank. coincidence?
66
Post by nodaytraderon Apr 25, 2023 10:57am

That’s Odd

At the opening, low bid was 29 cents and ask was 30 cents but the first trade, between Integral Financial and National Bank, was 500 at 28 cents. why would that be?
68
Post by SkywalkerofLukeon Apr 24, 2023 3:56pm

Recent News

AGN.c AGNPF (up 7% today) announced last week they received a Notice of Allowance from the US Patent and Trademark Office for patent application for its lead chronic kidney Disease (CKD) program drug ...more  
145
Post by XeniaTechieon Apr 21, 2023 11:37am

AGN receives US patent for CKD drug

Algernon Pharmaceuticals Inc.has received a Notice of Allowance from the United States Patent and Trademark Office for its lead drug NP-251 (Repirinast), a promising candidate for treating chronic ...more  
95
Post by SkywalkerofLukeon Apr 19, 2023 3:02pm

AGN Receives Notice of Allowance for its Lead CDK Drug

More than 1 in 7, that is 15% of US adults or 37 million people, are estimated to have chronic kidney disease and as many as 9 in 10 adults do not know they have it.  AGN.c AGNPF a Canadian ...more  
113
Comment by Pandoraon Apr 18, 2023 5:47pm

RE:News Update: $AGN CEO Chris Moreau - Patent NOA NP-251

Meanwhile, Chronic Cough anyone: T.BLU     Post by PressReleaseon Apr 18, 2023 12:11pm New Press Release - GSK reaches agreement to acquire late-stage biopharmaceutical ...more  
77
Discussion
Post by bmreedon Apr 18, 2023 12:21pm

News Update: $AGN CEO Chris Moreau - Patent NOA NP-251

News Update: Algernon Pharmaceuticals $AGN w CEO Christopher Moreau - Notice of Allowance from USPTO for NP-251 - https://youtu.be/Ot-kWEvA3m0   CEO Chris Moreau discusses Algernon's ...more  
247
Discussion
Post by StockHawk1on Apr 17, 2023 6:54pm

AGN Patent Application News Summary

Algernon Pharmaceuticals (AGN.c AGNPF) closed in the green today after announcing it  received a Notice of Allowance from the US Patent and Trademark Office for its patent application for its ...more  
176
Prev 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ... Next
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities